LCK and breast cancer: Notably, BC patients in cluster 1 were more sensitive to GW.441756 (TrkA inhibitor) and KIN001.135 (Lck inhibitor), while those in cluster 3 were more sensitive to BMS.754807(IGF-1R inhibitor), Bryostatin.1, CCT007093(PPM1D inhibitor), GSK269962A (Rho-associated protein kinase inhibitor), and LFM.A13(BTK inhibitor).